EGFR and non-small cell lung carcinoma: Among NSCLC cases with successful tissue EGFR testing using biopsy, an EGFR mutation was found in 31.6% of cases (12/38), whereas an EGFR sensitizing mutation was found in 20.7% of cases (11/53) that underwent plasma NGS testing.